A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma von Van Tine, Brian A., Agulnik, Mark, Olson, Richard D., Walsh, Gerald M., Klausner, Arthur, Frank, Nicole E., Talley, Todd T., Milhem, Mohammed M.

Volltext

So you want to start a biotech company von Chitale, Sadhana, Lawler, Colm, Klausner, Arthur

Volltext

Charting a course through a perfect storm von Klausner, Arthur

Volltext

Charting a course through a perfect storm: a venture capitalist gives his perspective on the outlook for life sciences ventures amid the perfect storm of the current economic downt... von Klausner, Arthur

Volltext

Mind the (biomedical funding) gap von Klausner, Arthur

Volltext

Mind the (biomedical funding) gap von Klausner, Arthur

Volltext

Mind the gap von Klausner, Arthur

Volltext

Mind the (biomedical funding) gap von Klausner, Arthur

Volltext

Mind the gap von Klausner, Arthur

Volltext

Mind the gap von Klausner, Arthur

Volltext

Mind the (biomedical funding) gap von Klausner, Arthur

Volltext

Mind the (biomedical funding) gap von Klausner, Arthur

Volltext

A phase 2 trial of 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and non-resectable soft tissue sarcomas von Van Tine, Brian Andrew, Agulnik, Mark, Olson, Richard D., Walsh, Gerald M., Klausner, Arthur, Milhem, Mohammed M.

Volltext

Biotech venture capital—it's not too late to be early von Klausner, Arthur

Volltext

Endotronics: Caught in a Tangled Web von Klausner, Arthur

Volltext

Will 1988 Be ‘The Year of the Liposome’? von Klausner, Arthur

Volltext

Varying Views of Genentech's Litigation von Klausner, Arthur

Volltext

Immunoassays Flourish in New Markets von Klausner, Arthur

Volltext

Commentary: Five Years in the Life von Klausner, Arthur

Volltext

Six Firms to Team Up on Fermentation von Klausner, Arthur

Volltext